Sacubitril/Valsartan for the Prevention and Treatment of Postinfarction Heart Failure: Ready to Use?

J Cardiovasc Pharmacol. 2021 Sep 1;78(3):331-333. doi: 10.1097/FJC.0000000000001103.
No abstract available

Publication types

  • Editorial

MeSH terms

  • Aminobutyrates / adverse effects
  • Aminobutyrates / therapeutic use*
  • Angiotensin II Type 1 Receptor Blockers / adverse effects
  • Angiotensin II Type 1 Receptor Blockers / therapeutic use*
  • Animals
  • Biphenyl Compounds / adverse effects
  • Biphenyl Compounds / therapeutic use*
  • Clinical Decision-Making
  • Disease Models, Animal
  • Drug Combinations
  • Evidence-Based Medicine
  • Heart Disease Risk Factors
  • Heart Failure / diagnosis
  • Heart Failure / mortality
  • Heart Failure / prevention & control*
  • Humans
  • Myocardial Infarction / diagnosis
  • Myocardial Infarction / drug therapy*
  • Myocardial Infarction / mortality
  • Neprilysin / antagonists & inhibitors
  • Protease Inhibitors / adverse effects
  • Protease Inhibitors / therapeutic use*
  • Protective Factors
  • Risk Assessment
  • Treatment Outcome
  • Valsartan / adverse effects
  • Valsartan / therapeutic use*

Substances

  • Aminobutyrates
  • Angiotensin II Type 1 Receptor Blockers
  • Biphenyl Compounds
  • Drug Combinations
  • Protease Inhibitors
  • Valsartan
  • Neprilysin
  • sacubitril and valsartan sodium hydrate drug combination